These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33929896)

  • 21. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
    Gattineni J; Bates C; Twombley K; Dwarakanath V; Robinson ML; Goetz R; Mohammadi M; Baum M
    Am J Physiol Renal Physiol; 2009 Aug; 297(2):F282-91. PubMed ID: 19515808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct and indirect effects of fibroblast growth factor 23 on the heart.
    Nakano T; Kishimoto H; Tokumoto M
    Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction.
    Smith ER; Holt SG; Hewitson TD
    Int J Biochem Cell Biol; 2017 Nov; 92():63-78. PubMed ID: 28919046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model.
    Toib A; Zhang C; Borghetti G; Zhang X; Wallner M; Yang Y; Troupes CD; Kubo H; Sharp TE; Feldsott E; Berretta RM; Zalavadia N; Trappanese DM; Harper S; Gross P; Chen X; Mohsin S; Houser SR
    Am J Physiol Heart Circ Physiol; 2017 Sep; 313(3):H620-H630. PubMed ID: 28646025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk between FGF23- and angiotensin II-mediated Ca
    Mhatre KN; Wakula P; Klein O; Bisping E; Völkl J; Pieske B; Heinzel FR
    Cell Mol Life Sci; 2018 Dec; 75(23):4403-4416. PubMed ID: 30062428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
    Yanucil C; Kentrup D; Campos I; Czaya B; Heitman K; Westbrook D; Osis G; Grabner A; Wende AR; Vallejo J; Wacker MJ; Navarro-Garcia JA; Ruiz-Hurtado G; Zhang F; Song Y; Linhardt RJ; White K; Kapiloff MS; Faul C
    Kidney Int; 2022 Aug; 102(2):261-279. PubMed ID: 35513125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR3 and FGFR4 do not mediate renal effects of FGF23.
    Liu S; Vierthaler L; Tang W; Zhou J; Quarles LD
    J Am Soc Nephrol; 2008 Dec; 19(12):2342-50. PubMed ID: 18753255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF23 impairs peripheral microvascular function in renal failure.
    Verkaik M; Juni RP; van Loon EPM; van Poelgeest EM; Kwekkeboom RFJ; Gam Z; Richards WG; Ter Wee PM; Hoenderop JG; Eringa EC; Vervloet MG;
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1414-H1424. PubMed ID: 30028196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
    Li H; Martin A; David V; Quarles LD
    Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization.
    Rivard K; Paradis P; Nemer M; Fiset C
    Cardiovasc Res; 2008 Apr; 78(1):53-62. PubMed ID: 18245065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor 23 and the heart.
    Faul C
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):369-75. PubMed ID: 22531163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CaMKII inhibition has dual effects on spontaneous Ca
    Sadredini M; Haugsten Hansen M; Frisk M; Louch WE; Lehnart SE; Sjaastad I; Stokke MK
    Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H446-H460. PubMed ID: 34270372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu.
    Figurek A; Rroji M; Spasovski G
    Cells; 2021 May; 10(5):. PubMed ID: 34065339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients.
    Girgis I; Gualberti J; Langan L; Malek S; Mustaciuolo V; Costantino T; McGinn TG
    Chest; 1997 Sep; 112(3):646-53. PubMed ID: 9315796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
    Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
    J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac actions of fibroblast growth factor 23.
    Faul C
    Bone; 2017 Jul; 100():69-79. PubMed ID: 27725315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
    Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 23 and Klotho contribute to airway inflammation.
    Krick S; Grabner A; Baumlin N; Yanucil C; Helton S; Grosche A; Sailland J; Geraghty P; Viera L; Russell DW; Wells JM; Xu X; Gaggar A; Barnes J; King GD; Campos M; Faul C; Salathe M
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.